Our finding of defective proteolysis of mTOR protein could be potentially exploited for improving the efficacy of breast cancer treatment regimens and mitigating drug resistance as well as providing a basis for potential novel therapeutic modalities for breast cancer. The gene discussed is MTOR; the disease is breast cancer.